Fat jab users will go to dodgy online sellers if Mounjaro rollout is botched by NHS, drug bosses warn
FAT JAB LOTTERY Fat jab users will go to dodgy online sellers if Mounjaro rollout is botched by NHS, drug bosses warn
FAT jab users will go to dangerous sellers if the Mounjaro rollout is botched by the NHS, drugs bosses warn.
Just eight of 42 health service boards offer the weight-loss injection after a launch in June, stats show.
Advertisement
Under current plans it will take 12 years for all the 3.4 million eligible people to get it.
Dr Emily Pegg of Lilly, which makes Mounjaro, told The Sun: 'We worry more people will be forced to seek it from potentially illegitimate and dangerous sources.'
Dr Pegg warned social media sellers and dodgy online pharmacies posed a threat.
She said: 'This is a prescription-only medication that comes with many rules and regulations.
Advertisement
"A lot of people who are buying illicit medicines may not realise the potential danger.'
Mounjaro is available on the NHS only to the most obese patients.
More than 1.5 million Britons are thought to be taking weight-loss drugs, mostly on private prescription.
Henry Gregg, from the National Pharmacy Association, said the NHS rollout was proceeding very slowly.
Advertisement
He added: 'There are concerning reports of clinically ineligible patients trying to source medication from unregulated sources.
'This could pose a serious risk to a patients' health.'
I've lost nearly 6 stone in 9 months on fat jabs - trolls call me 'lazy' & say it's the 'easy way out' but I don't care
A Department of Health spokesman said: 'We expect NHS boards to be making these drugs available.
"We are determined to bring revolutionary modern treatments to everyone who needs them.'
Advertisement
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
34 minutes ago
- Scottish Sun
New cancer treatment that slashes risk of death by a quarter gives fresh hope to thousands in ‘major step forward'
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) WOMEN with advanced womb cancer have been given fresh hope with the approval of a new drug. The treatment, which can slash the risk of death by 26 per cent, was given the green light for widespread NHS use. Sign up for Scottish Sun newsletter Sign up 1 Pembrolizumab, also known as Keytruda, has been licensed to treat advanced or recurring endometrial cancer Credit: Alamy Just 15 per cent of women live for five years if they have been diagnosed with advanced endometrial cancer - a cancer which usually starts in the lining of the womb. The National Institute for Health and Care Excellence (NICE) has now made a treatment, called pembrolizumab, available on the NHS in England for people with advanced or recurring endometrial cancer. The drug can slow down cancer growth and improve survival odds, health officials said. NICE estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment marks a "major step forward" in treatment for women with this type of cancer. Pembrolizumab, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug. This is a type of treatment that mobilises the body's own immune system to fight cancer. The drug is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given to patients for up to two years. According to NICE, clinical trials show the combination of treatments reduced the risk of death by 26 per cent compared to chemotherapy alone. The drug combo can also slow down cancer progression, the regulator added. Cervical cancer warning signs you should NEVER ignore, with Doctor Philippa Kaye Helen Knight, director of medicines evaluation at NICE, said: "For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option. "It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer." Around 9,700 women are diagnosed with endometrial cancer - also known as womb or uterine cancer - each year, making it the most common gynaecological cancer in the UK, according to NICE. The disease is most common in older women. Womb cancer symptoms Cancer of the womb is often called uterine or endometrial cancer. Symptoms include: Bleeding after the menopause Bleeding that is unusually heavy or persistent between periods Abnormal vaginal discharge (this might be pink) Anaemia High platelet count High blood sugar levels Stomach pain Swollen tummy Bloating Change in bowel or bladder habits A new cough Being overweight or obese is one of the biggest risks of womb cancer, according to Cancer Research UK. Other risk factors include age (most women diagnosed are aged 75 to 79) as well as being on hormone replacement therapy (HRT) and having diabetes or polycystic ovary syndrome (PCOS). Having too much of the hormone oestrogen is thought to raise your risk of womb cancer, according to the Eve Appeal. Fat cells in the body store oestrogen, even after the menopause and obesity has been linked to womb cancer because of its effect on oestrogen levels. It's not always possible to prevent womb cancer, but some things are thought to reduce your risk, like maintaining a healthy weight. Source: Cancer Research UK Its most common symptom is abnormal bleeding from the vagina, that is heavier than usual and occurs between periods or after menopause. It can also cause pink-tinged vaginal discharge, as well abdominal pain, bloating and a change in bladder or bowel habits. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: "Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. "It is great news that this new treatment has been approved. "It will offer hope, a better quality of life and improve outcomes for those affected."
The Sun
40 minutes ago
- The Sun
New cancer treatment that slashes risk of death by a quarter gives fresh hope to thousands in ‘major step forward'
WOMEN with advanced womb cancer have been given fresh hope with the approval of a new drug. The treatment, which can slash the risk of death by 26 per cent, was given the green light for widespread NHS use. 1 Just 15 per cent of women live for five years if they have been diagnosed with advanced endometrial cancer - a cancer which usually starts in the lining of the womb. The National Institute for Health and Care Excellence (NICE) has now made a treatment, called pembrolizumab, available on the NHS in England for people with advanced or recurring endometrial cancer. The drug can slow down cancer growth and improve survival odds, health officials said. NICE estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment marks a "major step forward" in treatment for women with this type of cancer. Pembrolizumab, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug. This is a type of treatment that mobilises the body's own immune system to fight cancer. The drug is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given to patients for up to two years. According to NICE, clinical trials show the combination of treatments reduced the risk of death by 26 per cent compared to chemotherapy alone. The drug combo can also slow down cancer progression, the regulator added. Cervical cancer warning signs you should NEVER ignore, with Doctor Philippa Kaye Helen Knight, director of medicines evaluation at NICE, said: "For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option. "It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer." Around 9,700 women are diagnosed with endometrial cancer - also known as womb or uterine cancer - each year, making it the most common gynaecological cancer in the UK, according to NICE. The disease is most common in older women. Womb cancer symptoms Cancer of the womb is often called uterine or endometrial cancer. Symptoms include: Bleeding after the menopause Bleeding that is unusually heavy or persistent between periods Abnormal vaginal discharge (this might be pink) Anaemia High platelet count High blood sugar levels Stomach pain Swollen tummy Bloating Change in bowel or bladder habits A new cough Being overweight or obese is one of the biggest risks of womb cancer, according to Cancer Research UK. Other risk factors include age (most women diagnosed are aged 75 to 79) as well as being on hormone replacement therapy (HRT) and having diabetes or polycystic ovary syndrome (PCOS). Having too much of the hormone oestrogen is thought to raise your risk of womb cancer, according to the Eve Appeal. Fat cells in the body store oestrogen, even after the menopause and obesity has been linked to womb cancer because of its effect on oestrogen levels. It's not always possible to prevent womb cancer, but some things are thought to reduce your risk, like maintaining a healthy weight. Its most common symptom is abnormal bleeding from the vagina, that is heavier than usual and occurs between periods or after menopause. It can also cause pink-tinged vaginal discharge, as well abdominal pain, bloating and a change in bladder or bowel habits. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: "Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. "It will offer hope, a better quality of life and improve outcomes for those affected."
Western Telegraph
an hour ago
- Western Telegraph
Treatment for advanced womb cancer ‘major step forward'
Just 15% of women live for five years if they have been diagnosed with advanced (stage four) endometrial cancer – a cancer which usually starts in the lining of the womb. The treatment, pembrolizumab, can slow down cancer growth and improve survival odds, health officials said. The National Institute for Health and Care Excellence (Nice) estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment for the NHS in England marks a 'major step forward' in treatment for women with this type of cancer. The treatment, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug and is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given for up to two years. Nice said that clinical trials show the combination of treatments reduced the risk of death by 26% compared to chemotherapy alone. The treatments can also slow down cancer progression, it added. 'For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option,' said Helen Knight, director of medicines evaluation at Nice. 'It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer.' Around 9,700 women are diagnosed with endometrial cancer each year, Nice said, making it the most common gynaecological cancer in the UK. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: 'Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. 'It is great news that this new treatment has been approved. 'It will offer hope, a better quality of life and improve outcomes for those affected.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'Getting this treatment to many more NHS patients as quickly as possible will help thousands of women live longer, allowing them to spend more time with loved ones and give them a better quality of life. 'Thanks to the NHS's Cancer Drugs Fund, it is now being fast-tracked into routine use, with treatment available to more patients from today.'
